research use only
Cat.No.S1036
| Related Targets | ERK p38 MAPK Raf JNK Ras KRas S6 Kinase MAP4K TAK1 Mixed Lineage Kinase |
|---|---|
| Other MEK Inhibitors | U0126-EtOH PD 98059 CI-1040 (PD184352) (E/Z)-BIX02189 Pimasertib (AS-703026) Refametinib (RDEA119) TAK-733 AZD8330 GDC-0623 SL-327 |
|
In vitro |
DMSO
: 96 mg/mL
(199.09 mM)
Ethanol : 96 mg/mL Water : Insoluble The solubility data above are all experimental results (not literature values). |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
Read more about PD0325901 (Mirdametinib) solubility in DMSO or water
Read more about PD0325901 (Mirdametinib) working concentrations for cell culture treatment
| Information | PD0325901 (Mirdametinib) is a potent, selective MEK1/2 inhibitor. It affects the MAPK/ERK signaling pathway by preventing ERK1/2 phosphorylation, effectively inhibiting cancer cell proliferation, migration, and inflammation, while promoting stem cell pluripotency. |
|---|---|
|
Read more about PD0325901 (Mirdametinib) IC50 for cell-based and cell-free assays |
|
| Primary Applications and Mechanism of Action | |
Read more about PD0325901 (Mirdametinib) Mechanism of Action
| Molecular Weight | 482.19 | Formula | C16H14F3IN2O4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 391210-10-9 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOCC(CO)O | ||
Read more comparative analysis about PD0325901 (Mirdametinib)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
Whether it interacts with other targets other than MEK?
Answer:
It has very high selectivity to MEK. In addition, this compound can also inhibits VEGF activity according to the reference: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713590/